Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

Company Overview

Titan Pharmaceuticals, founded in 1988 and headquartered in South San Francisco, is a clinical-stage biopharmaceutical company focused on the development and commercialization of sustained-release drug delivery systems. Its proprietary ProNeura® platform is designed to deliver therapeutic compounds consistently over extended periods—up to twelve months—addressing challenges associated with frequent dosing and patient adherence. This long-acting implant technology supports both small-molecule and peptide drugs, enabling more predictable pharmacokinetics and improved patient outcomes.

The company’s lead commercial product, Probuphine®, is a six-month subdermal implant for the treatment of opioid dependence. By continuously releasing buprenorphine, Probuphine aims to reduce the risk of diversion and misuse associated with daily dosing regimens. Titan originally secured U.S. regulatory approval for Probuphine in 2016 through a strategic partnership with Braeburn Pharmaceuticals, illustrating its collaborative approach to advancing clinical development, regulatory filings, manufacturing, and commercialization.

In addition to opioid dependence, Titan is advancing a pipeline of candidates targeting endocrine and neurological disorders, including Cushing’s disease and amyotrophic lateral sclerosis. All pipeline programs leverage the ProNeura platform to explore novel therapeutic applications and deliver candidates through preclinical and clinical stages. Titan has executed licensing and distribution agreements to broaden its geographic footprint, partnering with organizations in Europe, Asia, and Latin America to facilitate global development and market access.

Under the leadership of CEO Sunil Shah and a board comprising industry veterans in drug development and commercialization, Titan Pharmaceuticals remains committed to strategic partnerships and lean operations. The company’s R&D activities continue to be based in the San Francisco Bay Area, a leading biotechnology hub. With its focus on long-acting delivery technologies, Titan seeks to transform patient care by providing innovative, sustained-release therapies that meet unmet medical needs.

Key Stats

• Today's Range: $4.07 to $4.55
• 50-Day Range: $3.83 to $5.30
• 52-Week Range: $3.03 to $14.80
• Volume: 9,087 shs
• Average Volume: 138,002 shs
• Market Capitalization: $4.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Titan Pharmaceuticals Stock Analysis - MarketRank™

Titan Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Titan Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Titan Pharmaceuticals is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Titan Pharmaceuticals is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Titan Pharmaceuticals has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

328.56% of the float of Titan Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Titan Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Titan Pharmaceuticals has recently increased by 24,733.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Titan Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Titan Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

328.56% of the float of Titan Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Titan Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Titan Pharmaceuticals has recently increased by 24,733.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Titan Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Titan Pharmaceuticals this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Titan Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Titan Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.72% of the stock of Titan Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 31.49% of the stock of Titan Pharmaceuticals is held by institutions.

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed this year?

Titan Pharmaceuticals' stock was trading at $3.26 at the beginning of the year. Since then, TTNP stock has increased by 36.7% and is now trading at $4.4560.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its quarterly earnings data on Wednesday, May, 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals's stock reverse split on the morning of Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TTNP
• CIK: 910267
• Web: www.titanpharm.com
• Phone: (650) 244-4990
• Fax: 650-244-4956
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($4.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -145.92%
• Return on Assets: -129.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.73
• Quick Ratio: 7.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 914,000
• Free Float: 907,000
• Market Cap: $4.07 million
• Optionable: Optionable
• Beta: 1.27